Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 790-792, 2012.
Artículo
en Chino
| WPRIM
| ID: wpr-307293
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer.</p><p><b>METHODS</b>From January 2006 to January 2010, 90 patients with recurrent hepatocellular carcinoma (HCC) were treated with MCT and TACE in our hospital. The treatment group received sorafenib + MCT + TACE, and the control group received MCT + TACE.</p><p><b>RESULTS</b>RR of the treatment group was 66.7%, which of the control group was 52.0% (P > 0.05). DCR was 83.3% in the treatment group and 64.5% in the control group (P < 0.05). Through a comparison of survival curves along with the extension of time, the survival rates of the two groups were decreased, but the treatment group (group 1) had a significantly higher one than the control group (group 2), with a statistically significant difference (P < 0.05).</p><p><b>CONCLUSION</b>Sorafenib combined with MCT and TACE can improve the disease control rate and prolong the survival in patients with recurrent HCC.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Compuestos de Fenilurea
/
Cirugía General
/
Terapéutica
/
Inducción de Remisión
/
Doxorrubicina
/
Tasa de Supervivencia
/
Estudios de Seguimiento
/
Carboplatino
/
Quimioembolización Terapéutica
/
Ablación por Catéter
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Límite:
Adulto
/
Anciano
/
Femenino
/
Humanos
/
Masculino
Idioma:
Chino
Revista:
Chinese Journal of Oncology
Año:
2012
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS